These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 3315512)

  • 1. The clinical utility of C-peptide measurement in the care of patients with diabetes.
    Jones AG; Hattersley AT
    Diabet Med; 2013 Jul; 30(7):803-17. PubMed ID: 23413806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twenty-four hour urinary C-peptide and fasting plasma C-peptide as indicators of metabolic control in 83 insulin dependent diabetic patients.
    Yoo HJ; Hartling SG; Binder C
    Korean J Intern Med; 1987 Jul; 2(2):196-200. PubMed ID: 3154831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postprandial C-peptide to glucose ratio as a predictor of β-cell function and its usefulness for staged management of type 2 diabetes.
    Lee EY; Hwang S; Lee SH; Lee YH; Choi AR; Lee Y; Lee BW; Kang ES; Ahn CW; Cha BS; Lee HC
    J Diabetes Investig; 2014 Sep; 5(5):517-24. PubMed ID: 25411619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of factors influencing postprandial C-peptide levels in Japanese patients with type 2 diabetes: Comparison with C-peptide levels after glucagon load.
    Funakoshi S; Fujimoto S; Hamasaki A; Fujiwara H; Fujita Y; Ikeda K; Takahara S; Seino Y; Inagaki N
    J Diabetes Investig; 2011 Nov; 2(6):429-34. PubMed ID: 24843526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes.
    Funakoshi S; Fujimoto S; Hamasaki A; Fujiwara H; Fujita Y; Ikeda K; Takahara S; Nagashima K; Hosokawa M; Seino Y; Inagaki N
    J Diabetes Investig; 2011 Aug; 2(4):297-303. PubMed ID: 24843502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients.
    Gillard P; Hilbrands R; Van de Velde U; Ling Z; Lee DH; Weets I; Gorus F; De Block C; Kaufman L; Mathieu C; Pipeleers D; Keymeulen B
    Diabetes Care; 2013 Nov; 36(11):3483-8. PubMed ID: 24041683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control.
    Radtke MA; Nermoen I; Kollind M; Skeie S; Sørheim JI; Svartberg J; Hals I; Moen T; Dørflinger GH; Grill V
    Diabetes Care; 2010 Mar; 33(3):589-94. PubMed ID: 20028939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients.
    Vandemeulebroucke E; Keymeulen B; Decochez K; Weets I; De Block C; Féry F; Van de Velde U; Vermeulen I; De Pauw P; Mathieu C; Pipeleers DG; Gorus FK;
    Diabetologia; 2010 Jan; 53(1):36-44. PubMed ID: 19898832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute insulin response to intravenous glucose, glucagon and arginine in some subjects at risk for type 1 (insulin-dependent) diabetes mellitus.
    Bardet S; Rohmer V; Maugendre D; Marre M; Semana G; Limal JM; Allannic H; Charbonnel B; Saï P
    Diabetologia; 1991 Sep; 34(9):648-54. PubMed ID: 1955097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
    Scheen AJ; Castillo MJ; Lefèbvre PJ
    Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research.
    Polonsky KS
    Diabetes; 1995 Jun; 44(6):705-17. PubMed ID: 7789637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reproducibility of beta-cell function estimates in non-insulin-dependent diabetes mellitus.
    Gjessing HJ; Damsgaard EM; Matzen LE; Frøland A; Faber OK
    Diabetes Care; 1987; 10(5):558-62. PubMed ID: 3315512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men.
    Chen KW; Boyko EJ; Bergstrom RW; Leonetti DL; Newell-Morris L; Wahl PW; Fujimoto WY
    Diabetes Care; 1995 Jun; 18(6):747-53. PubMed ID: 7555498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The beta-cell response to glucagon and mixed meal stimulation in non-insulin dependent diabetes.
    Gjessing HJ; Damsgaard EM; Matzen LE; Faber OK; Frøland A
    Scand J Clin Lab Invest; 1988 Dec; 48(8):771-7. PubMed ID: 3070718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic B-cell function in non-insulin-dependent diabetes mellitus during successive periods of sulfonylurea and insulin treatment: serum C-peptide response to glucagon and urine C-peptide excretion.
    Hsieh SD; Iwamoto Y; Matsuda A; Kuzuya T
    Endocrinol Jpn; 1987 Aug; 34(4):561-7. PubMed ID: 3315640
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.